期刊文献+

艾普拉唑治疗十二指肠球部溃疡的疗效观察 被引量:6

The clinical efficacy of ilaprazole in the treatment of duodenal bulb ulcer
原文传递
导出
摘要 目的:比较艾普拉唑和奥美拉唑三联疗法治疗幽门螺杆菌( Hp )阳性十二指肠球部溃疡的疗效。方法100例Hp阳性的十二指肠球部溃疡患者采用抽签法随机分为两组,分别给予艾普拉唑或奥美拉唑为基础的三联疗法治疗,5周后复查胃镜和13 C呼气试验,观察Hp根除率、1周和5周症状缓解率、溃疡愈合率和药物不良反应。结果艾普拉唑组和奥美拉唑组的Hp根除率分别为92%、78%(χ^2=3.853,P<0.05);溃疡愈合率分别为96%、90%(χ^2=1.561,P>0.05);治疗1周症状缓解率分别为92.3%、86.8%(上腹痛),89.7%、73.3%(反酸),88.9%、75.0%(烧灼感);两组均未发现严重不良反应。结论艾普拉唑+阿莫西林+克林霉素三联疗法是根除Hp的理想方案。 Objective To compare the clinical efficacy of ilaprazole standard triple therapy with omeprazole standard triple therapy in the treatment of patients with Helicobacter pylori ( Hp ) positive duodenal bulb ulcer. Methods 100 patients with Hp positive duodenal bulb ulcer were randomly divided into the two groups by lottery, given ilaprazole standard triple therapy and omeprazole standard triple therapy respectively.After 5 weeks of the course,take gastroscopy and the enzyme 13C-urea breath test,and the Hp eradication rate,clinical efficacy,ulcer heal-ing rate and adverse reactions were observed.Results The Hp eradication rate is better than the omeprazole group (92%vs 78%,χ^2=3.853,P〈0.05),while the ulcer healing rate were no significant (96%vs 90%,χ^2=1.561, P〉0.05).Conclusion It is a good method in the treatment of Hp positive duodenal bulb ulcer for ilaprazole stand-ard triple therapy.
出处 《中国基层医药》 CAS 2014年第22期3381-3383,共3页 Chinese Journal of Primary Medicine and Pharmacy
关键词 十二指肠溃疡 幽门螺杆菌 艾普拉唑 奥美拉唑 Duodenal ulcer Helicobacter pylori Ilaprazole Omeprazole
  • 相关文献

参考文献14

  • 1艾普拉唑治疗十二指肠溃疡及CYP2C19代谢型对疗效影响的多中心临床研究[J].中华消化内镜杂志,2009,26(9):475-479. 被引量:18
  • 2艾普拉唑肠溶片治疗十二指肠溃疡的多中心、随机、双盲、阳性平行对照临床研究[J].中华消化杂志,2009,29(8):542-546. 被引量:25
  • 3无,刘文忠,谢勇,成虹,吕农华,胡伏莲,张万岱,周丽雅,陈烨,曾志荣,王崇文,萧树东,潘国宗,胡品津.第四次全国幽门螺杆菌感染处理共识报告[J].中华内科杂志,2012,51(10):832-837. 被引量:843
  • 4Hunt RH,Xiao SD,Megraud F,Leon-Barua R,Bazzoli F,van der Merwe S,Vaz Coelho LG,Fock M,Fedail S,Cohen H,Malfertheiner P,Vakil N,Hamid S,Goh KL,Wong BCY,Krabshuis J,Le Mair A,杜颖,戴宁.世界胃肠病学组织全球指南——发展中国家幽门螺杆菌感染[J].胃肠病学,2011,16(7):423-428. 被引量:27
  • 5Malfertheiner P, Peitz U, Treiber G. What constitutes failure for Helicobacter pylori eradication therapy [ J ]. Can J Gastroenterol, 2003,17 ( Suppl B ) :53 B-57.
  • 6B. Li Y, Zhang W, Guo D, et al. Pharmacokinetics of the new proton- pump inhibitor ilaprazole in Chinese healthy subjects in relation to CYP3A5 and CYP'2C19 genotypes[ J]. Clin Chim Acta,2008, 391 (1/2) :60-67.
  • 7Zendehdel N, Biramijamal F, Hossein-Nezhad A, et al. Role of cy- tochrome P450 2C19 genetic polymorphisms in the therapeutic efl:caey of omeprazole in Iranian patients with erosive reflux esopbagitis [ J]. Archi Irani Med ,2010,13 (5) :407-412.
  • 8Lee JH,Jung HY,Ghoi HJ,et al. The influence of CYP2C19 poly-morphismon eradication of Helicobacter pylori : a prospective ran- domized study of lansoprazole and rabeprasolc[ J]. Gut and Liv- er,2010,4(2) :201-206.
  • 9Ulrich K, Matthias S, Gerhard T. CYP2C19 polymorphism and protonpump inhihitors [ J 1. Pharm Toxico1,2004,95 ( 1 ) :2-8.
  • 10Cho H,Choi MK,Cho DY,et al. Effect of CYP2C19 genetic poly- morphismon pharmacokinetics and pharmacodynamics of a new protonpump inhibitor,ilaprasole [ J ]. J Clin Pharmaco1,2011,18.

二级参考文献53

共引文献919

同被引文献67

  • 1Wang L, Zhou L, Lin S, et al.A new PP1, ilaprazole compared with omeprazole in the treatment of duodenal ulcer: a randomized double-blind multicenter trial[J].J Clin Gastroenterol, 2011, 45 ( 4 ) : 322-329.
  • 2Ho K Y, Kuan A, Zano F, et al.Randomized, parallel, double- blind comparison of the ulcer-healing effects of ilaprazole and omeprazole in the treatment of gastric and duodenal ulcers[J].J Gastroenterol, 2009, 44 ( 7 ) : 697-707.
  • 3Sachs G, Shin J M, Howden C W.Review article: the clinical pharmacology of proton pump inhibitors[J].Aliment Pharmacol Ther, 2006, 23 ( suppl 2 ) : 2-8.
  • 4Shi S, Klotz U.Proton pump inhlbitors: an update of their clinical use and pharmacokinetics[J].Eur J Clin Pharmacol, 2008, 64 ( 10 ) : 935-951.
  • 5Kwon D, Chae J B, Park C W, et al.Effects of IY-81149, a newly developed proton pump inhibitor, on gastric acid secretion in vitro and in vivo[J].Arzneimittelforschung, 2001, 51 ( 3 ) : 204-213.
  • 6Li Y, Zhang W, Guo D, ct al.Pharmacokinetics of the new proton pump inhibitor ilaprazole in chinese healthy subjects in relation to CYP3A5 and CYP2C19 genotypea[J].Clin Chim Acta, 2008, 391 ( 1/2 ) : 60-67.
  • 7Wang L, Zhou L, Hu H, et al.Ilaprazole for the treatment of duodenal ulcer: a randomized, double-blind and controlled phase llI trial[J].Curr Med Res Opin, 2012, 28 ( 1 ) : 101-109.
  • 8DeCarvalho K I M, Bonamin F, DosSantos R C, et al.Geraniol-- a flavoring agent with multifunctional effects in protecting the gastric and duodenal mucosa[J].Naunyn Schmiedebergs Arch Pharmacol, 2014, 387 (4) : 355-365.
  • 9Linn K A, Guenther J, Pagel P S, et al.Hematemesis and free air under the diaphragm: Just another perforated duodenal ulcer or something more unusual[J].Journal of Cardiothoracic and Vascular Anesthesia, 2014, 28 ( 1 ) : 200-201.
  • 10Park C H, Bae S H, Kim H Y, et al.Hepatohiliary and pancreatic: bleeding duodenal ulcer associated with coil migration after transarterial chemoembolization and radiotherapy[J].Journal of Gastroenterology and Hepatology, 2014, 29 ( 5 ) : 897.

引证文献6

二级引证文献63

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部